Ralinepag, formerly known as APD-811, is an orally bioavailable agonist of the prostacyclin (IP) receptor, is an investigational drug candidate internally discovered and developed by Arena and intended for the treatment of vasospastic diseases, such as Pulmonary Arterial Hypertension. Ralinepag has the potential to mimic prostacyclin, the major product of cyclooxygenase in macrovascular endothelium, which elicits a potent vasodilation and inhibition of platelet aggregation when binding to this receptor. References:

纯度：≥98%

CAS：1187856-49-0